REG - Hutchmed China Ltd - Director's Share Dealing

HUTCHMED (China)Announcement

08/03/2023 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230308:nRSH2733Sa&default-theme=true

RNS Number : 2733S  Hutchmed (China) Limited  08 March 2023

Director's Share Dealing

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 8, 2023:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that Mr
Johnny Cheng, Executive Director and Chief Financial Officer, sold a total of
1,300,000 Ordinary Shares of US$0.10 each of the Company at an average price
of HK$27.073 per Ordinary Shares on March 3, 2023  and March 6, 2023.

 

Following the above sale of 1,300,000 Ordinary Shares, the holding of Mr Cheng
is 1,261,460 Ordinary Shares and 274,493 ADSs (Note), representing
approximately 0.3% of the current issued share capital of the Company.

 

Note: 274,493 ADSs included (i) 41,552 ADSs currently held by Mr Cheng, (ii)
217,800 ADSs granted under Share Option Scheme and (iii) 15,141 ADSs as
beneficiary of a trust under long term incentive plan.

 

The notifications set out below are provided in accordance with the
requirements of the EU Market Abuse Regulation.

 

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Mr Johnny Cheng

 2    Reason for the notification

 a)   Position/status                                               Executive Director and Chief Financial Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Ordinary Shares of US$0.10 each

      Identification code

                                                                    DI ISIN: KYG4672N1198

 b)   Nature of the transaction                                     Sale of 830,000 Ordinary Shares on March 3, 2023 at an average price of

                                                             HK$27.101.

 c)   Price(s) and volume(s)
                                                                                         Price(s)             Volume(s)
                                                                                         HK$26.850            50,000 Ordinary Shares
                                                                                         HK$26.950            20,000 Ordinary Shares
                                                                                         HK$27.000            110,000 Ordinary Shares
                                                                                         HK$27.005            50,000 Ordinary Shares
                                                                                         HK$27.015            20,000 Ordinary Shares
                                                                                         HK$27.016            40,000 Ordinary Shares
                                                                                         HK$27.027            30,000 Ordinary Shares
                                                                                         HK$27.050            10,000 Ordinary Shares
                                                                                         HK$27.091            200,000 Ordinary Shares
                                                                                         HK$27.100            50,000 Ordinary Shares
                                                                                         HK$27.113            100,000 Ordinary Shares
                                                                                         HK$27.150            20,000 Ordinary Shares
                                                                                         HK$27.200            30,000 Ordinary Shares
                                                                                         HK$27.300            40,000 Ordinary Shares
                                                                                         HK$27.450            10,000 Ordinary Shares
                                                                                         HK$27.500            20,000 Ordinary Shares
                                                                                         HK$27.656            20,000 Ordinary Shares
                                                                                         HK$27.700            10,000 Ordinary Shares

 d)   Aggregated information                                        Aggregated volume: 830,000 Ordinary Shares

                                                             Price information: HK$22,494,120
      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2023-03-03

 f)   Place of the transaction                                      Hong Kong Stock Exchange

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Ordinary Shares of US$0.10 each

      Identification code

                                                                    DI ISIN: KYG4672N1198

 b)   Nature of the transaction                                     Sale of 470,000 Ordinary Shares on March 6, 2023 at an average price of

                                                             HK$27.022.

 c)   Price(s) and volume(s)
                                                                                         Price(s)             Volume(s)
                                                                                         HK$26.850            30,000 Ordinary Shares
                                                                                         HK$26.900            10,000 Ordinary Shares
                                                                                         HK$26.908            10,000 Ordinary Shares
                                                                                         HK$26.950            70,000 Ordinary Shares
                                                                                         HK$27.000            50,000 Ordinary Shares
                                                                                         HK$27.050            68,500 Ordinary Shares
                                                                                         HK$27.060            200,000 Ordinary Shares
                                                                                         HK$27.100            20,000 Ordinary Shares
                                                                                         HK$27.250            10,000 Ordinary Shares
                                                                                         HK$27.300            1,500 Ordinary Shares

 d)   Aggregated information                                        Aggregated volume: 470,000 Ordinary Shares

                                                             Price information: HK$12,700,455
      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2023-03-06

 f)   Place of the transaction                                      Hong Kong Stock Exchange

 

Aggregated volume: 830,000 Ordinary Shares

Price information: HK$22,494,120

 

e)

 

Date of the transaction

 

2023-03-03

 

 

f)

 

Place of the transaction

 

Hong Kong Stock Exchange

 

4

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.10 each

 

 

DI ISIN: KYG4672N1198

 

b)

 

Nature of the transaction

 

 

Sale of 470,000 Ordinary Shares on March 6, 2023 at an average price of
HK$27.022.

 

 

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

 

 

HK$26.850

30,000 Ordinary Shares

 

 

HK$26.900

10,000 Ordinary Shares

 

 

HK$26.908

10,000 Ordinary Shares

 

 

HK$26.950

70,000 Ordinary Shares

 

 

HK$27.000

50,000 Ordinary Shares

 

 

HK$27.050

68,500 Ordinary Shares

 

 

HK$27.060

200,000 Ordinary Shares

 

 

HK$27.100

20,000 Ordinary Shares

 

 

HK$27.250

10,000 Ordinary Shares

 

 

HK$27.300

1,500 Ordinary Shares

 

 

 

 

 

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

Aggregated volume: 470,000 Ordinary Shares

Price information: HK$12,700,455

 

e)

 

Date of the transaction

 

2023-03-06

 

 

f)

 

Place of the transaction

 

Hong Kong Stock Exchange

 

 
About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 5,000
personnel across all its companies, at the center of which is a team of about
1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Contacts
 Investor Enquiries
 Mark Lee, Senior Vice President                  +852 2121 8200
 Annie Cheng, Vice President                      +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles, Solebury Trout            +1 (917) 570 7340 (Mobile)

bmiles@soleburystrat.com
 Europe - Ben Atwell / Alex Shaw, FTI Consulting  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                  +44 7779 545 055 (Mobile)

HUTCHMED@fticonsulting.com
 Asia - Zhou Yi, Brunswick                        +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,                +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHNKFBDOBKKDNK